NYMC Faculty Publications
Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic Malignancies
Author Type(s)
Faculty
DOI
10.2217/fon-2021-0576
Journal Title
Future Oncology
First Page
3549
Last Page
3560
Document Type
Article
Publication Date
9-2021
Department
Pediatrics
Second Department
Health Behavior and Community Health
Abstract
NKTR-255 is an investigational polyethylene glycol-modified recombinant human IL-15 (rhIL-15) receptor agonist, designed to improve the immunotherapeutic and anti-cancer benefit observed with rhIL-15 while circumventing the toxicities associated with this therapy. In preclinical studies, NKTR-255 has demonstrated enhanced proliferation and function of CD8+ T cells and natural killer cells, as well as enhanced anti-tumor activity and survival both as monotherapy and in combination with monoclonal antibodies in multiple cancer models. Here, we describe the rationale and design of the first-in-human Phase I, dose-escalation and dose-expansion study of NKTR-255 alone and in combination with daratumumab or rituximab in adults with relapsed/refractory multiple myeloma or non-Hodgkin's lymphoma that will determine the maximum tolerated dose and recommended Phase II dose for NKTR-255.
Recommended Citation
Shah, N., Perales, M., Turtle, C. J., Cairo, M. S., Cowan, A. J., Saeed, H., Budde, L. E., Tan, A., Lee, Z., Kai, K., Marcondes, M. Q., Zalevsky, J., Tagliaferri, M. A., & Patel, K. K. (2021). Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic Malignancies. Future Oncology, 17 (27), 3549-3560. https://doi.org/10.2217/fon-2021-0576
